Pages that link to "Q57781187"

The following pages link to 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: Relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms (Q57781187):

Displaying 48 items.

• 3H-Spiperone labels sigma receptors, not dopamine D2 receptors, in rat and human lymphocytes (Q23922388) (← links)
• Potassium chloride depolarization mediates CREB phosphorylation in striatal neurons in an NMDA receptor-dependent manner (Q28346834) (← links)
• Structural and functional brain imaging in schizophrenia (Q33396727) (← links)
• Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol (Q33437467) (← links)
• Striatal dopamine D2 receptors in tardive dyskinesia: PET study (Q33627591) (← links)
• Schizophrenia: D4 receptor elevation. What does it mean? (Q33921370) (← links)
• Hippocampal neurons in schizophrenia (Q34383604) (← links)
• Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia (Q34383654) (← links)
• Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution (Q34540452) (← links)
• Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials (Q34703195) (← links)
• Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials (Q35071909) (← links)
• PET imaging of dopamine receptors in human basal ganglia: relevance to mental illness (Q36586088) (← links)
• Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model (Q36727004) (← links)
• Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. (Q36955877) (← links)
• Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia (Q37596400) (← links)
• Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia. (Q38305872) (← links)
• Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system (Q38346296) (← links)
• Proteome and pathway effects of chronic haloperidol treatment in mouse hippocampus. (Q38399332) (← links)
• Chemical brain anatomy in schizophrenia (Q40473365) (← links)
• Dopamine in schizophrenia (Q40918315) (← links)
• Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells (Q41286489) (← links)
• The neuroanatomy and neurochemistry of schizophrenia (Q41743479) (← links)
• Hyperactive behavioural effects induced by intranigral infusion of a pyridinium metabolite of haloperidol in rats (Q42551036) (← links)
• Plasma homovanillic acid in untreated schizophrenia--relationship with symptomatology and sex. (Q43564923) (← links)
• Decreased [(3)H]spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study (Q43942876) (← links)
• Long-term treatment with the tetrahydropyridine analog (HPTP) of haloperidol influences dopamine ligand binding in baboon brain. An [123I]iodobenzamide (IBZM) SPECT study (Q46677709) (← links)
• The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. (Q48247779) (← links)
• A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis (Q48312237) (← links)
• Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia (Q48326374) (← links)
• Dopamine D2 densities and the schizophrenic brain. (Q48404440) (← links)
• D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after (Q48471657) (← links)
• Brain imaging of schizophrenia--the dopamine hypothesis (Q48532685) (← links)
• Increased [3H] raclopride binding sites in postmortem brains from schizophrenic violent suicide victims (Q48591328) (← links)
• Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness (Q48777045) (← links)
• Presynaptic dopaminergic function in the striatum of schizophrenic patients (Q48802317) (← links)
• Comparison of the in vitro receptor binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes (Q48854657) (← links)
• In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia (Q49068786) (← links)
• The neuropsychology of schizophrenia: A perspective from neurobehavioral genetics (Q56896418) (← links)
• Why don't preschizophrenic children have delusions and hallucinations? (Q57403541) (← links)
• (3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients (Q57781184) (← links)
• Excitatory amino acids, NMDA and sigma receptors: A role in schizophrenia? (Q60513754) (← links)
• Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a post mortem study (Q61713976) (← links)
• The limbic-striatal interaction: A seesaw rather than a tandem (Q63866035) (← links)
• The neurotensin antagonist SR 48692 fails to modify the behavioural responses to a dopamine D1 receptor agonist in the rat (Q73326319) (← links)
• Dysregulation of dopamine and pathology of prefrontal neurons: neuroimaging studies in schizophrenia and related animal models (Q73528520) (← links)
• The Dopamine Hypothesis and Neurophysiology Concepts in Schizophrenia (Q84076757) (← links)
• A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter (Q90427479) (← links)
• A focused update on tardive dyskinesia (Q97092488) (← links)